๐ฐ Stephens Yoder News
Page 2 - Stephens Yoder News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Stephens Yoder. Real-time updates on events, politics, business and more.
March 1, 2022
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON TUESDAY, MARCH 1, 2022 AT 8:00 AM ESTInitiated efficacy part of phase 2a study of PRS-060/AZD1402; expected topline readout this yearDosed first patient in
January 3, 2022
BOSTON, MA / ACCESSWIRE / January 3, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology
November 2, 2021
Company To Host an Investor Conference Call on Tuesday, November 2, 2021 at 8:00 AM EDTDosing completed in part 1a of phase 2a study of PRS-060/AZD1402Dosing to begin this quarter in phase 2 study of cinrebafusp
October 6, 2021
BOSTON, MA / ACCESSWIRE / October 6, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology
May 25, 2021
Pieris Pharmaceuticals Announces Respiratory and Ophthalmology Collaboration with Genentech ACCESSWIRE 25 May 2021, 22:05 GMT+10 Pieris will receive $20 million as an upfront payment and is eligible to receive more than $1.4 billion in additional potential milestone payments plus royalties for commercialized programs Collaboration includes initial programs in respiratory disease and ophthalmology, with opportunity to nominate additional programs BOSTON, MA / ACCESSWIRE / May 25, 2 021 / Pieris...
May 17, 2021
Pieris Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update ACCESSWIRE 17 May 2021, 21:05 GMT+10 COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON MONDAY, MAY 17, 2021 AT 8:00 AM EDT PRS-060/AZD1402 dosed to first patient in phase 2a study Cinrebafusp alfa (PRS-343) phase 2 study expected to begin this summer Announced license and collaboration agreement with Boston Pharmaceuticals for PRS-342, a preclinical 4-1BB/GPC3 immuno-oncology bispecific; Pieris to re...
April 12, 2021
Penny Stocks To Buy According To Analysts Whether you love penny stocks or hate them, you canรขยยt argue with the fact that big money can be made. By definition, the term itself references stocks to buy for less than $5. So even the slightest 50 cent move from the highest-priced penny stock is a near-market-beating gain. For the most part, newer retail traders actively learn how to day trade and start by focusing on cheap stocks to watch. Since it doesnรขยยt take a whole lot of capital to ...
April 10, 2021
Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Presents Updated Phase 1 Monotherapy Data for 4-1BB/HER2 Bispecific Cinrebafusp Alfa and Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/S095012 at 2021 AACR Annual Meeting Durable anti-tumor activity in heavily pre-treated patient population ?including "cold" and HER2-low expressing tumors Dose-dependent immune activation and 4-1BB modulation in both HER2-high and HER2-low expressing patients PRS-344/S095012 preclinical BOSTON, MA / ACC...